For example, KRAS mutations are used to guide treatment with Sotorasib, while tumor expression of (wild type) human epidermal growth factor receptor 2 and 3 (HER2 and HER3) are used to select patients for trastuzumab and cetuximab, respectively. The gene discussed is ERBB3; the disease is neoplasm.